Effect of rTPA (recombinant tissue Plasminogen Activator) in patients with ischemic stroke

The evaluation of effect of rTPA (recombinant tissue Plasminogen Activator) in clinical manifestations and prognosis of patients with ischemic stroke

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20160318027097N10

Enrollment

100

Registered

2018-06-01

Start date

2018-05-22

Completion date

Unknown

Last updated

2018-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebellar stroke. Cerebellar stroke syndrome

Interventions

Intervention group: Recombinant tissue Plasminogen Activator (rTPA), 0.9 mg/Kg, intravenous, Single dose.

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients with ischemic stroke Referring to the hospital less than 4.5 hours Indication of rtPA injection with no evidence of hemorrhage on theinitial brain image

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
The stroke clinical manifestations. Timepoint: Befor the intervention, 24 hours, 48 hours, 168 hours, 1 month, 2 months, 3 months after the intervention. Method of measurement: National Institutes Of Health Stroke Scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Afshan Sharghi

Ardabil University of Medical Sciences

naghizadeh73@yahoo.com+98 45 3351 2000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026